FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type: (check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product Type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 
 

1  What was the best response to HSCT, excluding any planned post-HSCT therapy, since the date of the last report?

    
 nmlkji

complete response - absence of all signs and/or symptoms of Langerhans cell histiocytosis  

 nmlkji
partial response - regression of signs and/or symptoms of disease without appearance of new lesions  

 nmlkji
stable disease - persistence of signs and/or symptoms of disease without appearance of new lesions  

 nmlkji
mixed response - regression of some signs and/or symptoms of disease with appearance of new lesions  

 nmlkji
progressive disease - progression of signs and/or symptoms of disease initially detected and/or reappearance of old and/or appearance of new lesions  

 nmlkji
Unknown  

 nmlkji
Not evaluable  

 
 
2  Specify reason:    

 
 
3  Specify the date best response was determined: __ __ __ __ - __ __- __ __  

 
 

4  Did the disease recur or progress since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the organ(s) involved in the disease recurrence or progression: 
 

5  Bone

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

6  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Langerhans Cell Histiocytosis Post-HSCT Data Questions: 1 - 53

Form 2140 R2.0: Langerhans Cell Histiocytosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2140 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 4



 
 

7  Central nervous system

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

8  Gastrointestinal tract

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

9  Liver

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

10  Lung

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

11  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

12  Skin

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

13  Spleen

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

14  Other organ

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
15  Specify:    

 
 
16  Specify the date disease recurrence or progression was determined: __ __ __ __ - __ __- __ __  

 
 

17  Was any additional treatment specifically for LCH given since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  

  
 
18  Specify the date treatment started: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 

Specify any additional drugs given since the date of the last report: 
 

19  2 CdA (cladribine)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

20  Chlorambucil (Leukeran)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

21  Cyclosporin-A (CsA)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

22  Etoposide (VP-16)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

23  Mercaptopurine (6-MP, Purinethol)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

24  Steroids

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

25  Vinblastine (Velban)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

26  Other drug

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
27  Specify:    

Form 2140 R2.0: Langerhans Cell Histiocytosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2140 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 4



 
 

28  Was radiation given since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the site(s) of radiation: 
 

29  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 
30  Total cGy (rads) given:    

 
 

31  Central nervous system

    
 nmlkji

yes  
 nmlkji

no  

 
 
32  Total cGy (rads) given:    

 
 

33  Gastrointestinal tract

    
 nmlkji

yes  
 nmlkji

no  

 
 
34  Total cGy (rads) given:    

 
 

35  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 
36  Total cGy (rads) given:    

 
 

37  Lung

    
 nmlkji

yes  
 nmlkji

no  

 
 
38  Total cGy (rads) given:    

 
 

39  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

 
 
40  Total cGy (rads) given:    

 
 

41  Skin

    
 nmlkji

yes  
 nmlkji

no  

 
 
42  Total cGy (rads) given:    

 
 

43  Spleen

    
 nmlkji

yes  
 nmlkji

no  

 
 
44  Total cGy (rads) given:    

 
 

45  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
46  Total cGy (rads) given:    

 
 

47  Specify the fractionation schedule:

    
 nmlkji

single  
 nmlkji

single daily  
 nmlkji

multiple daily  
 nmlkji

other schedule  

 
 

48  Was any other treatment for LCH administered?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
49  Specify other treatment:    

 
 

50  Are any of the additional treatments still currently being administered?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2140 R2.0: Langerhans Cell Histiocytosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2140 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 4



 
 

51  What is the current status of Langerhans cell histiocytosis?

    
 nmlkji

complete response - absence of all signs and/or symptoms of Langerhans cell histiocytosis  

 nmlkji
partial response - regression of signs and/or symptoms of disease without appearance of new lesions  

 nmlkji
stable disease - persistence of signs and/or symptoms of disease without appearance of new lesions  

 nmlkji
mixed response - regression of some signs and/or symptoms of disease with appearance of new lesions  

 nmlkji
progressive disease - progression of signs and/or symptoms of disease initially detected and/or reappearance of old and/or appearance of new lesions  

 nmlkji
Unknown  

 nmlkji
Not evaluable  

 
 
52  Specify reason:    

 
 
53  Specify the date the current disease status was determined: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone:    

 
Fax:    

 
 
E-mail address:    

Form 2140 R2.0: Langerhans Cell Histiocytosis Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2140 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 4